Boundless Bio, a clinical stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced two upcoming poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, MA.
Details of the presentations are as follows:
Title: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)
Abstract Number: B082
Session: Poster Session B
Date/Time: Friday, October 13 | 12:30 – 4:00 pm ET
Title: Intrinsic genomic plasticity of extrachromosomal DNA (ecDNA) enables oncogene amplified tumor cells to develop rapid acquired resistance to targeted therapy
Abstract Number: B092
Session: Poster Session B
Date/Time: Friday, October 13 | 12:30 – 4:00 pm ET
About Boundless Bio
Boundless Bio is a clinical-stage precision oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is being evaluated in a Phase 1/2 clinical trial, and has multiple other pipeline programs advancing in preclinical development and discovery. To date, Boundless Bio has raised more than $250 million from leading life sciences investors.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231004561743/en/
Contacts
James Lee, Boundless Bio
jlee@boundlessbio.com
Media
1AB
Dan Budwick
dan@1abmedia.com
